Entegris (ENTG) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
31 Oct, 2025Executive summary
Q3 2025 net sales were $807.1M, nearly flat year-over-year and up sequentially, with GAAP diluted EPS of $0.46 and non-GAAP EPS of $0.72, both meeting guidance.
Net income for Q3 2025 was $70.5M, down from $77.5M a year ago, while adjusted (non-GAAP) net income was $109.9M.
Record operating cash flow was achieved, with strong momentum in advanced node products and a leadership transition to a new CEO focused on growth and value creation.
The company completed restructuring initiatives, including workforce reductions and asset impairments, and divested the PIM business, impacting year-over-year comparability.
For the nine months ended September 27, 2025, net sales were $2,372.7M and net income was $186.2M.
Financial highlights
Gross margin for Q3 2025 was 43.5% (GAAP) and 43.6% (non-GAAP), down from 46.0% a year ago, mainly due to underutilization of manufacturing facilities.
Adjusted EBITDA for Q3 2025 was $220.7M (27.3% margin), down 5% year-over-year but up sequentially.
Free cash flow for Q3 2025 was $191M, the highest in six years, driven by inventory reduction.
Operating income for Q3 2025 was $122.6M (15.2% margin), compared to $136.2M (16.9% margin) in Q3 2024.
Cash and cash equivalents at quarter-end were $399.8M; long-term debt was $3,842.8M.
Outlook and guidance
Q4 2025 sales expected between $790M and $830M; GAAP EPS guidance is $0.35–$0.42, non-GAAP EPS is $0.62–$0.69.
Adjusted EBITDA margin for Q4 2025 is projected at 26.5%–27.5%.
CapEx is expected to materially decrease year-over-year as the company exits a major investment cycle, with existing capacity supporting higher revenue.
Management expects continued near-term headwinds from global trade tensions, supply chain challenges, and semiconductor market volatility.
Non-GAAP tax rate to normalize at ~15% in Q4.
Latest events from Entegris
- Abstentions and broker non-votes now count against eliminating supermajority requirements.ENTG
Proxy filing26 Mar 2026 - Annual meeting to vote on directors, compensation, auditor, and key shareholder rights changes.ENTG
Proxy filing23 Mar 2026 - Proxy covers leadership transition, governance reforms, and performance-based compensation changes.ENTG
Proxy filing23 Mar 2026 - Strategic growth, governance reforms, and enhanced ESG drive long-term value creation.ENTG
Proxy Filing6 Mar 2026 - Q4 2025 delivered strong sales and margins, with robust 2026 guidance and ongoing deleveraging.ENTG
Q4 202510 Feb 2026 - Q2 sales rose sequentially with strong margins; Q3 guidance and investments support further growth.ENTG
Q2 20242 Feb 2026 - Adjusted sales up 7% year-over-year; Q4 outlook signals margin strength and cost savings.ENTG
Q3 202417 Jan 2026 - Q4 2024 delivered double-digit adjusted sales growth and margin expansion, beating guidance.ENTG
Q4 20248 Jan 2026 - Q2 2025 sales were $792.4M, with Q3 non-GAAP EPS guided at $0.68–$0.75.ENTG
Q2 202517 Dec 2025 - Strong 2024 growth, robust governance, and key votes on directors, pay, auditor, and voting rights.ENTG
Proxy Filing1 Dec 2025